- 期刊
Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis
延伸閱讀
- Bates, T. M. G., Lehmann, G. M., Haidaris, P. J. S., Bernstein, S. H., Sime, P. J., & Phipps, R. P. (2008). Role of Peroxisome Proliferator-Activated Receptor Gamma and Its Ligands in the Treatment of Hematological Malignancies. PPAR Research, 2008(), 120-137-113. https://doi.org/10.1155/2008/834612
- Agius, L. M. (2012). Neuroinflammation as the Proximate Cause of Signature Pathogenic Pattern Progression in Amyotrophic Lateral Sclerosis, Aids, and Multiple Sclerosis. Pathology Research International, 2012(), 28-32. https://doi.org/10.1155/2012/169270
- 劉濟弘（2021）。Effects of Peroxisome Proliferator-activated Receptor-γ Modulating Drugs on Stroke Prevention in Diabetic Patients。台灣中風醫誌，3(4)，195-200。https://doi.org/10.6318/FJS.202112_3(4).0002
- Elyaman, W., Khoury, S. J., Scott, D. W., & Groot, A. S. D. (2011). Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis. Neurology Research International, 2011(), 48-53. https://doi.org/10.1155/2011/256460
- Cheng, W., & Chen, G. (2014). Chemokines and Chemokine Receptors in Multiple Sclerosis. Mediators of Inflammation, (2014-6), 369-376. https://doi.org/10.1155/2014/659206